Ironwood Pharmaceuticals | IRWD - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Akebia Therapeutics USD 23.53M 3.19M 2025-12
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Amarin USD 18.97M 1.03M 2025-12
Ardelyx USD 75.92M 7.69M 2025-12
Astellas Pharma JPY 234.7B 12.92B 2026-03
AstraZeneca USD 5.06B 455M 2026-03
Charles River Laboratories USD 159.42M 36.71M 2026-03
Coherus Biosciences USD 15M 6.26M 2025-12
Emergent BioSolutions USD 182.8M 82.3M 2023-06
Esperion Therapeutics USD 39.42M 456K 2025-12
Halozyme Therapeutics USD 46.29M 18.35M 2026-03
Incyte USD 328.1M 62.31M 2026-03
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
Lexicon Pharmaceuticals USD 3.98M 195K 2025-12
MacroGenics USD 7.94M 1.96M 2025-12
Moderna USD 173M 135M 2026-03
Myriad Genetics USD 122.3M 6.7M 2025-12
Pacira USD 83.88M 7.99M 2026-03
PTC Therapeutics USD 73.89M 13.31M 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
Takeda JPY 292B 9.21B 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12